ASN-90 is under clinical development by Grupo Ferrer Internacional and currently in Phase II for Progressive Supranuclear Palsy. According to GlobalData, Phase II drugs for Progressive Supranuclear Palsy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ASN-90 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-90 overview
ASN-90 is under development for the treatment of Progressive Supranuclear palsy (PSP). It is administered orally. It is a small molecule act by targeting O-GlcNAcase (O-linked-beta-N-acetylglucosaminidase). It was also under development for the treatment of Primary age related tauopathy, Alzheimer’s Disease and frontotemporal dementia.
Grupo Ferrer Internacional overview
Grupo Ferrer Internacional (Ferrer) manufactures and markets pharmaceuticals and chemicals products. The company offers its products for various therapeutic areas including cardiovascular, central nervous system, oncology, dermatology, gastrointestinal, phlebology, musculoskeletal system, pain, paediatrics and the respiratory system. It also provides over-the-counter medicines, dermo-cosmetics, food supplements, cough syrups and expectorants, anti-lice and insect repellent products, infant nutrition products, and other skincare products. Ferrer offers its products under Nucleo, Keltican, Nubit, Somazina, Ceraxon, Zynapse, Hidrasec, Tiorfan, Gelocatil, Abfentiq, and Kaptic brand names. The company also offers diagnostics services through its subsidiary Ferrer inCode. The company operates production facilities in Spain and the US. Ferrer is headquartered in Barcelona, Spain.
For a complete picture of ASN-90’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
